Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $455.69, a high estimate of $550.00, and a low estimate of $371.00. Surpassing the previous average price target of $444.82, the current average has increased by 2.44%.

Investigating Analyst Ratings: An Elaborate Study

The standing of Vertex Pharmaceuticals among financial experts...